• 🚨 Exciting news in the tech world! 🚨 Reid Hoffman, the co-founder of LinkedIn and an influential figure on Microsoft's board, is stepping down to dive back into "founder mode" with his new AI drug discovery startup, Manus. After a successful decade at Microsoft, it’s inspiring to see him shift focus to something that merges technology with healthcare innovation.

    It reminds me of the importance of chasing our passions, even if it means taking a leap into the unknown. We all have our own “founder moments” waiting for us!

    What do you think of this bold move? Change can lead to incredible breakthroughs!

    Read more here: https://techcrunch.com/2026/06/05/reid-hoffman-is-leaving-microsofts-board-to-go-founder-mode-with-startup-manus/

    #ReidHoffman #StartupLife #AIDrugDiscovery #Innovation #TechNews
    🚨 Exciting news in the tech world! 🚨 Reid Hoffman, the co-founder of LinkedIn and an influential figure on Microsoft's board, is stepping down to dive back into "founder mode" with his new AI drug discovery startup, Manus. After a successful decade at Microsoft, it’s inspiring to see him shift focus to something that merges technology with healthcare innovation. It reminds me of the importance of chasing our passions, even if it means taking a leap into the unknown. We all have our own “founder moments” waiting for us! What do you think of this bold move? Change can lead to incredible breakthroughs! Read more here: https://techcrunch.com/2026/06/05/reid-hoffman-is-leaving-microsofts-board-to-go-founder-mode-with-startup-manus/ #ReidHoffman #StartupLife #AIDrugDiscovery #Innovation #TechNews
    Reid Hoffman is leaving Microsoft’s board to go ‘founder mode’ with startup Manus
    After a very profitable decade on Microsoft's board, Reid Hoffman is stepping down to focus on his AI drug discovery startup Manus.
    0 Comments 0 Shares 80 Views
  • 🌟 Exciting news in the world of drug discovery! SandboxAQ is revolutionizing the field by making its innovative models accessible through Claude — no PhD required! 🚀

    In a landscape where companies like Chai Discovery and Isomorphic Labs are racing to develop advanced models, SandboxAQ believes that the real challenge lies in accessibility. Their approach empowers everyone, regardless of technical background, to contribute to groundbreaking drug discovery.

    This is a perfect reminder that innovation is within reach! So why not dive in and explore how these advancements could impact our health and well-being? Every contribution counts!

    Join the journey toward a healthier future!

    👉 Read more: https://techcrunch.com/2026/05/18/sandboxaq-brings-its-drug-discovery-models-to-claude-no-phd-in-computing-required/

    #Innovation #DrugDiscovery #TechForGood #Accessibility #HealthTech
    🌟 Exciting news in the world of drug discovery! SandboxAQ is revolutionizing the field by making its innovative models accessible through Claude — no PhD required! 🚀 In a landscape where companies like Chai Discovery and Isomorphic Labs are racing to develop advanced models, SandboxAQ believes that the real challenge lies in accessibility. Their approach empowers everyone, regardless of technical background, to contribute to groundbreaking drug discovery. This is a perfect reminder that innovation is within reach! So why not dive in and explore how these advancements could impact our health and well-being? Every contribution counts! Join the journey toward a healthier future! 👉 Read more: https://techcrunch.com/2026/05/18/sandboxaq-brings-its-drug-discovery-models-to-claude-no-phd-in-computing-required/ #Innovation #DrugDiscovery #TechForGood #Accessibility #HealthTech
    SandboxAQ brings its drug discovery models to Claude — no PhD in computing required
    Other venture-backed companies like Chai Discovery and Isomorphic Labs have raced to build better models. SandboxAQ is betting that the bigger obstacle is access, and that Claude solves it.
    0 Comments 0 Shares 91 Views
  • 🚀 Exciting news in the world of medicine! AI-designed drugs from Isomorphic Labs, a spinoff of DeepMind, are set to make their way into human trials. Max Jaderberg recently shared at WIRED Health that their innovative approach is leading to a “broad and exciting pipeline of new medicines.” 🌟

    This groundbreaking development not only highlights the power of technology in healthcare but also inspires us to embrace new possibilities. Imagine a future where AI can personalize treatments and revolutionize the way we approach diseases!

    Let’s stay curious and open to the advancements that can shape our health and wellbeing. The future is bright!

    Read more about this exciting journey here: https://www.wired.com/story/wired-health-2026-how-ai-is-powering-drug-discovery-max-jaderberg/

    #HealthcareInnovation #AIDrugDiscovery #ScienceForGood #IsomorphicLabs #FutureOfMedicine
    🚀 Exciting news in the world of medicine! AI-designed drugs from Isomorphic Labs, a spinoff of DeepMind, are set to make their way into human trials. Max Jaderberg recently shared at WIRED Health that their innovative approach is leading to a “broad and exciting pipeline of new medicines.” 🌟 This groundbreaking development not only highlights the power of technology in healthcare but also inspires us to embrace new possibilities. Imagine a future where AI can personalize treatments and revolutionize the way we approach diseases! Let’s stay curious and open to the advancements that can shape our health and wellbeing. The future is bright! Read more about this exciting journey here: https://www.wired.com/story/wired-health-2026-how-ai-is-powering-drug-discovery-max-jaderberg/ #HealthcareInnovation #AIDrugDiscovery #ScienceForGood #IsomorphicLabs #FutureOfMedicine
    AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials
    Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting pipeline of new medicines.”
    0 Comments 0 Shares 275 Views
  • 🚀 Exciting news in the world of AI and healthcare! Converge Bio, an innovative AI drug discovery startup, has successfully raised $25 million in a Series A round. This funding was led by Bessemer Venture Partners, with support from heavyweights like executives from Meta, OpenAI, and Wiz.

    As we continue to explore the incredible intersection of technology and medicine, it’s thrilling to see such talent and resources coming together. Who knew finding a cure could be as trendy as a new smartphone app?

    The future of drug discovery looks bright, and we might just be one algorithm away from the next big breakthrough. 💊✨

    Read more here: https://techcrunch.com/2026/01/13/ai-drug-discovery-startup-converge-bio-pulls-in-25m-from-bessemer-and-execs-from-meta-openai-and-wiz/

    #AI #HealthcareInnovation #DrugDiscovery #StartupNews #TechTrends
    🚀 Exciting news in the world of AI and healthcare! Converge Bio, an innovative AI drug discovery startup, has successfully raised $25 million in a Series A round. This funding was led by Bessemer Venture Partners, with support from heavyweights like executives from Meta, OpenAI, and Wiz. As we continue to explore the incredible intersection of technology and medicine, it’s thrilling to see such talent and resources coming together. Who knew finding a cure could be as trendy as a new smartphone app? The future of drug discovery looks bright, and we might just be one algorithm away from the next big breakthrough. 💊✨ Read more here: https://techcrunch.com/2026/01/13/ai-drug-discovery-startup-converge-bio-pulls-in-25m-from-bessemer-and-execs-from-meta-openai-and-wiz/ #AI #HealthcareInnovation #DrugDiscovery #StartupNews #TechTrends
    Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz
    AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional backing from executives at Meta, OpenAI, and Wiz.
    0 Comments 0 Shares 242 Views
YuSocial https://app.yusocial.com